Cell Signaling Technology

Product Pathways - Apoptosis

DR5 Antibody #3696

Applications Reactivity Sensitivity MW (kDa) Source
W H Endogenous 40, 48 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

DR5 Antibody detects the precursor and mature forms of isoforms 1 and 2 of DR5. Cross reactivity was not detected with other family members.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding cysteine 248 of isoform 1 of human DR5. Antibodies were purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells either mock transfected or transfected with a DR5 cDNA, using DR5 Antibody.

Western Blotting

Western Blotting

Western blot analysis of extracts from HT1080 and HepG2 cell lines, using DR5 Antibody.

Background

The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases.

DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been been shown to induce apoptosis in variety of cell types and has been targeted for cancer therapy (1-5). Structurally, DR5 contains an amino-terminal leader cleavage site followed by an extracellular region containing two cysteine-rich repeats, then a central transmembrane domain and a carboxy-terminal death domain. DR5 is expressed in a wide variety of tissues and is transcriptional target for p53 (6-8). It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli (9).

  1. Nagata, S. (1997) Cell 88, 355-365.
  2. Thorburn, A. (2004) Cell. Signal. 16, 139-144.
  3. Wiley, S.R. et al. (1995) Immunity 3, 673-82.
  4. Walczak, H. et al. (1997) EMBO J. 16, 5386-97.
  5. Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
  6. MacFarlane, M. et al. (1997) J. Biol. Chem. 272, 25417-20.
  7. Wu, G.S. et al. (2000) Adv. Exp. Med. Biol. 465, 143-51.
  8. Wu, G.S. et al. (1997) Nat. Genet. 17, 141-3.
  9. Finnberg, N. et al. (2005) Mol. Cell Biol. 25, 2000-13.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products